Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Netherlands Ministry of Health Welfare and Sport
  • Dutch Cancer Society

This publication has 38 references indexed in Scilit: